Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat
Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat
Related Posts
Dubai draws Swiss family offices tired of tax and regulation
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.…
Donald Trump and the long history of ‘sticky’ US tariffs
In a matter of weeks, President Donald Trump’s tariff blitz has erased a century of US trade liberalisation. Economists say…
Nearly 20 million jobs are on the chopping block to be replaced by AI, SHRM research shows
New research from the Society for Human Resource Management (SHRM) finds that 12.6% of current roles in the US are…